

Prescription Drugs

PHOTOCOPY
PRESERVATION

File prescription
drug

DISTURBING TRUTHS AND DANGEROUS TRENDS:

**The Facts About Medicare Beneficiaries and
Prescription Drug Coverage**

*National Economic Council
Domestic Policy Council*

July 22, 1999

DISTURBING TRUTHS AND DANGEROUS TRENDS: The Facts About Medicare Beneficiaries and Prescription Drug

Table of Contents

Overview	i
Importance of Prescription Drugs to Medicare Beneficiaries	1
Prescription Drug Spending by Medicare Beneficiaries	3
Coverage for Prescription Drugs for Medicare Beneficiaries	4
◦ Retiree Health Coverage	5
◦ Medigap Prescription Drug Coverage	6
◦ Medicare Managed Care	7
◦ Medicaid	8
◦ Beneficiaries Lacking Drug Coverage	9
President's Proposed Prescription Drug Benefit	10
Appendix: Methodology & Endnotes	11

OVERVIEW

DISTURBING TRUTHS AND DANGEROUS TRENDS: The Facts About Medicare Beneficiaries and Prescription Drug

This report describes the inadequate and unstable nature of the prescription drug coverage currently available to Medicare beneficiaries. Prescription drugs have never been more important, but the people who rely on them most – the elderly and people with disabilities – increasingly find themselves uninsured or with coverage that is becoming more expensive and less meaningful. This report shows that the accessing essential prescription drugs is not only a problem for the millions of Medicare beneficiaries without any insurance – it is an increasing challenge for beneficiaries who have coverage. Key findings of the report include:

- **Prescription drug coverage is good medicine.**
 - Part of modern medicine. Prescription drugs serve as complements to medical procedures, such as anti-coagulants, used with heart valve replacement surgery; substitutes for surgery, such as lipid lowering drugs that reduce the need for bypass surgery; and new treatments where there previously were none, such as medications used to manage Parkinson's disease. In addition, as our understanding of genetics grows, the possibility for breakthrough pharmaceutical and biotechnology will increase exponentially.
 - Medicare beneficiaries are particularly reliant on prescription drugs. Not only do the elderly and people with disabilities have more problems with their health, but these problems tend to include conditions that respond to drug therapy. Not surprisingly, about 85 percent of beneficiaries fill at least one prescription a year for such conditions as osteoporosis, hypertension, myocardial infarction (heart attacks), diabetes, and depression.
 - The lack of drug coverage has led to inappropriate use of medications which can result in increased costs and unnecessary institutionalization. Recent research has determined that being uninsured leads to significant declines in the use of necessary medications. The consequence of inappropriate and underutilization of prescription drugs has also been found to double the likelihood that low-income beneficiaries entering nursing homes. One study concluded that drug-related hospitalization accounted for 6.4 percent of all admissions of the over 65 population and estimated that over three-fourths of these admissions could have been avoided with proper use of necessary medications.
- **About 75 percent of Medicare beneficiaries lack decent, dependable, private-sector coverage of prescription drug coverage.**
 - Only one-fourth of Medicare beneficiaries have retiree drug coverage, which is the only meaningful form of private coverage.

- Over three-fourths of beneficiaries lack decent, dependable. At least one-third of Medicare beneficiaries have no drug coverage at all. Another 8 percent purchase Medigap with drug coverage – but this coverage is frequently expensive, inaccessible and inadequate for many Medicare beneficiaries. About 17 percent have coverage through Medicare managed care. Given the projected leveling off of managed care enrollment and actual declines in the scope of managed care drug benefits, this source of coverage is unstable. Drug coverage in managed care can only be assured if it becomes part of Medicare's basic benefits and is explicitly paid for in managed care rates. The remaining 17 percent are covered through Medicaid, Veterans' Affairs and other public programs.
- **Private trends: Decline in coverage and affordability.**
 - The proportion of firms offering retiree health coverage has declined by 25 percent in the last four years. Retiree health coverage is declining substantially because many firms previously providing it are opting to drop their coverage. The decline was more pronounced among the largest employers (greater than 5,000 employees), over a third of whom dropped coverage in this period.
 - Medigap premiums for drugs are high and increase with age. Medigap premiums vary widely throughout the nation but are consistently two to three times higher than the Medicare premium proposed by the President. Moreover, unlike the President's proposal, premiums substantially increase with age as virtually every Medigap plan "age rates" the cost of the premium. This means that just as beneficiaries need prescription drug coverage most and are the least likely to be able to afford it, this drug coverage is being priced out of reach. This cost burden will particularly affect women, who make up 73 percent of people over age 85.
- **Public drug coverage trends: managed care benefits reduced.**
 - The value of Medicare managed care drug benefits is declining. Nearly three-fifths of plans are reporting that they will cap prescription drug benefits below \$1,000 in the year 2000. This is part of a troubling trend of plans to severely limit benefits through low caps. In fact, the proportion of plans with \$500 or lower benefit caps will increase by over 50 percent between 1998 and 2000.
 - Participation by Medicaid eligible populations remains low. Millions of Medicare beneficiaries under 75 percent of poverty (about \$6,000 for a single, \$8,500 for a couple) are eligible for Medicaid prescription drug coverage, but the participation rate is only about 40 percent. This contrasts with an almost 100 percent participation rate in Medicare Part B for beneficiaries. Inadequate outreach and welfare stigma contributes to these low participation levels and raise serious questions about the feasibility and advisability of using the Medicaid program to provide needed coverage for a population at higher income levels.

- Millions of beneficiaries have no drug coverage.
 - At least 13 million Medicare beneficiaries have absolutely no prescription drug coverage. The number of the uninsured is not concentrated among the low income. In fact, the income distribution of uninsured Medicare beneficiaries is almost exactly the same for beneficiaries at all income levels.
 - More than half of Medicare beneficiaries without drug coverage are middle class. Over 50 percent of Medicare beneficiaries without drug coverage have incomes in excess of 150 percent – an annual income of approximately \$17,000 for couples. This clearly indicates that any prescription drug coverage policy that limits coverage to below 150 percent of poverty, as some in Congress suggest, will leave the vast majority of the Medicare population unprotected.

IMPORTANCE OF PRESCRIPTION DRUGS TO MEDICARE BENEFICIARIES


- **Part of modern medicine.** Prescription drugs serve as complements to medical procedures (e.g., anti-coagulants with heart valve replacement surgery); substitutes for surgery and other medical procedures (e.g., lipid lowering drugs that lessen need for bypass surgery) and new treatments where there previously were none (e.g, drugs for HIV and Parkinson's). Some of the major advances in public health -- the near eradication of polio and measles and the decline in infectious diseases -- are largely the result of vaccines and antibiotics. And, as the understanding of genetics increases, the possibility for pharmaceutical and biotechnology interventions will multiply.
- **Greatest need for prescription drugs.** The elderly and people with disabilities are particularly reliant on prescription drugs. Not only do they experience greater health problems, but these problems tend to include conditions that respond to drug therapy. As a result, about 85 percent of beneficiaries fill at least one prescription a year. Some examples of common conditions include:
 - Osteoporosis: Over 1 in 5 older women have osteoporosis and about 15 percent have suffered a fracture as a result.¹ It is a leading risk factor for hip fractures, which affects 225,000 people over the age of 50. Estrogen replacement can reduce the risk of osteoporosis as well as that of cardiovascular disease. One commonly used drug costs \$20 per month, \$240 per year.
 - Hypertension: About 60 percent of people over age 65 have hypertension.² African Americans are more likely to have hypertension. For a person over age 55, hypertension increases the risk of a heart attack or other heart problem over 10 years by 10 percent.³ Hypertension roughly doubles the risk of cardiovascular disease and is the leading factor for stroke. According to one study, treatment results in a one-third reduction in the probability of stroke and a one-quarter reduction in the probability of a heart attack.⁴ ACE inhibitors which typically cost \$40 per month, \$480 per year are commonly prescribed to control hypertension, and are frequently used in combination with diuretics and /or beta-blockers.
 - Myocardial Infarction (Heart Attack): Heart disease is the leading cause of death for persons 65 and over. About 1.5 million Americans each year have heart attacks, which are fatal in about 30 percent of patients. Since people who survive heart attacks are much more likely to have subsequent attacks, disease management including drugs can significantly improve health and longevity. For example, a study of the use of a lipid lowering drug by people who had an acute myocardial infarction found a 42 percent reduction in coronary mortality after 5 years of follow-up.⁵ A common lipid reduction drug costs about \$85 per month, \$1,020 per year. A beta-blocker costs about \$30 per month, \$360 per year, and can reduce long-term mortality by 25 percent.⁶
 - Adult-Onset Diabetes: About 1 in 10 elderly have Type I or II diabetes.⁷ Diabetes can lead to blindness, kidney disease and nerve damage. Glucose (blood sugar)

control can prevent or delay these conditions. Commonly used medications include cost around \$60 per month, \$720 per year.

- Depression: An estimated 1 in 10 to 1 in 20 community-based elderly experience depression.⁸ Depression can lead to institutionalization and other health problems. From 60 to 75 percent of patients respond to drug therapy.⁹ New therapies can cost from \$130 to \$290 per month or \$1,560 to \$3,480 per year.
- **Many beneficiaries need drugs but do not use them as prescribed because they do not have well managed, affordable drug insurance.** Most research has found that drug coverage influences use of needed drugs:
 - Decreased use of needed medications. Elderly and disabled Medicaid beneficiaries experienced significant declines in the use of essential medicines (e.g., insulin, lithium, cardiovascular agents, bronchodilators) when their Medicaid drug coverage was limited.¹⁰ Many elderly must choose between prescriptions and other basic household needs.¹¹
 - Increased nursing home use. Medicare beneficiaries whose Medicaid drug coverage was limited were twice as likely to enter nursing homes.¹²
 - Less protection against drug complications. Even though the elderly and disabled take more prescription drugs and have more complex medical problems, Medicare beneficiaries without coverage do not benefit from drug management. This could lead to adverse drug reactions, inappropriate use of drugs, or discontinuation of needed drugs. One study which classified the geriatric admissions to a community hospital found that drug-related hospitalization accounted for 6.4 percent of all admissions among the over 65 population. The study estimated that 76 percent of these admissions were avoidable.¹³

PRESCRIPTION DRUG SPENDING BY MEDICARE BENEFICIARIES


- Because of their greater need, the elderly and people with disabilities have greater health care costs. The elderly's per capita spending on drugs is over three times higher than that of non-elderly adults. While only 12 percent of the entire population, the elderly account for about one-third of drug spending.



- Over one-third (38%) of Medicare beneficiaries will spend more than \$1,000 on prescription drugs. Less than 5 percent will spend more than \$5,000.
- The average total drug costs for Medicare beneficiaries is estimated to approach \$1,100 in 2000. Over 85 percent of Medicare beneficiaries will spend money on prescription drugs, and more than half will spend more than \$500.
- Spending is higher for women. Because of their greater likelihood of living longer and having chronic illness, women on Medicare spend nearly 20 percent more on prescription drugs than men.
- Out-of-pocket spending is also high. In 2000, Medicare beneficiaries are estimated to spend about \$525 on prescription drugs out-of-pocket. This spending is linked to insurance coverage – it is much higher for those with no coverage (\$800) and people with Medigap (\$650) than those with retiree coverage (\$400).

COVERAGE FOR PRESCRIPTION DRUGS FOR MEDICARE BENEFICIARIES


- Unlike virtually all private health insurance plans, Medicare does not cover prescription drugs. As a result, a fragmented, unstable system of coverage has emerged as beneficiaries attempt to insure against the costs of medications.



- Only one-fourth of Medicare beneficiaries have retiree drug coverage. Employers provide health insurance for most Americans under the age of 65, but pay for supplemental coverage for only a fraction of their elderly retirees. When available, this coverage tends to have reasonable cost sharing and affordable premiums.
- About 75 percent of Medicare beneficiaries lack decent, dependable, private-sector coverage of prescription drugs. These beneficiaries include those with:
 - Medigap. About 8 percent of beneficiaries purchase Medigap with drug coverage – but this coverage is frequently expensive, inaccessible and inadequate for many Medicare beneficiaries.
 - Medicare managed care. About 17 percent of beneficiaries have coverage through Medicare managed care. Given the projected leveling off of managed care enrollment and actual declines in the scope of managed care drug benefits, this source of coverage is unstable.
 - Medicaid and other public programs. Medicaid covers about 12 percent of beneficiaries and programs like the Veterans' Administration cover another 5 percent of beneficiaries. Eligibility for these programs is very restrictive.
 - No coverage at all. 34 percent of Medicare beneficiaries has no drug coverage.

RETIREE HEALTH COVERAGE

- About one in four Medicare beneficiaries has prescription drug coverage through their retiree health plan. These employer-based plans offer decent, affordable coverage.



- Firms offering retiree health coverage have declined by 25 percent in the last four years.¹⁴ Retiree health coverage is declining substantially because many firms previously providing it are opting to drop their coverage.
 - The decline was more pronounced among the largest employers (greater than 5,000 employees), over a third of whom dropped coverage in this period.
- Most serious effect will occur when the baby boom generation retires. Although there are employers who are dropping health coverage for current retirees, most are restricting coverage for future retirees. This means that the access problems that are emerging now could be more severe in the future.
- Firms are increasingly moving their retirees to Medicare managed care. To help constrain costs, a number of employers are providing incentives for their retirees to join managed care. The number of large employers offering Medicare managed care plans rose from 7 percent in 1993 to 38 percent in 1996.¹⁵


MEDIGAP PRESCRIPTION DRUG COVERAGE

- Because of its high cost relative to its benefit, less than one in ten Medicare beneficiaries purchases a Medigap plan with prescription drugs. Three of the ten standardized Medicare supplemental plans, (plans H, I, and J) include prescription drug coverage. All three plan types have a \$250 deductible for the drug benefit and require 50 percent coinsurance. The H and I plans have a cap on drug benefits of \$1,250 while the J plan caps the benefit at \$3,000. The typical premium for a plan with the lower cap costs about \$90 per month or \$1,080 per year.
- Medigap is expensive, inefficient, and often uses higher prices to discriminate against the oldest beneficiaries.

- Expensive. Medigap policies that cover prescription drugs are expensive relative to comparable policies that do not cover drugs. Additionally, premiums vary tremendously from place to place, and from beneficiary to beneficiary. Finally, a beneficiary cannot only pay for prescription drugs – they must also buy the other benefits in the package.


Beneficiaries With Medigap Still Pay High Out-Of-Pocket Drug Costs

Medigap Annual Premiums And Out-Of-Pocket Spending



SOURCE: Actuarial Research Corporation for HRB. Premium from Texas for a 75 year old. Base is \$161 per month, drug addition is \$101 per month.

Medigap Premiums For Drugs Are High And Increase With Age, 1999




Sample Premiums for 1999. Difference between Plan I (\$1,250 benefit limit) and Plan F, which is similar but has no drug coverage. These premiums will be higher in 2002, when the President's proposed drug benefit will cost \$24 per month.

Inefficient. Because it is sold to individuals, Medigap does not offer beneficiaries the kind of premiums that result from group purchasing. This also adds to the administrative costs per policy, which are typically two to three times more than that of group coverage.


Costs increase with age as well as health inflation. This "attained age" pricing practice causes excessive premiums for those who need it most – the very old. It also disproportionately affects women since they comprise nearly three-fourths of people over age 85.

MEDICARE MANAGED CARE

- The number of beneficiaries with drug coverage through Medicare managed care has risen to 17 percent. Most Medicare managed care plans offer prescription drugs. Drug coverage is one of the major attractions for beneficiaries to enroll in these plans.
- Drug coverage under Medicare+Choice is unstable. Managed care plans are not required to offer a drug benefit, but can do so with any excess Medicare payments or by charging a premium. This results in wide variation across areas, since payments vary by area, and over time.




- The value of Medicare managed care drug benefits is declining. Nearly three-fifths of plans are reporting that they will cap prescription drug benefits below \$1,000 in the year 2000. The proportion of plans with \$500 or lower benefit caps will increase by over 50 percent between 1998 and 2000. This is part of a troubling trend of plans to severely limit benefits through low caps.
- Plans dropping out of Medicare limit access to drugs. Nearly 50,000 Medicare beneficiaries will lose access to Medicare managed care next year as plans withdraw from particular areas or Medicare altogether.



MEDICAID

- About 12 percent of Medicare beneficiaries are also fully eligible for Medicaid and its drug benefit. Most of these “dual eligibles” qualify for Medicaid because they receive Supplemental Security Income due to low income (on average, about 73 percent of poverty -- \$6,200 for a single, \$8,300 for a couple in 2000). States have other options for covering the elderly and disabled, including “medically needy” or “spend-down” programs that extend eligibility to sick and/or institutionalized people.



- Participation by Medicaid eligible populations remains low. Millions of Medicare beneficiaries under 75 percent of poverty (about \$6,000 for a single, \$8,500 for a couple) are eligible for Medicaid prescription drug coverage, but the participation rate is only about 40 percent.
 - Lack of information, ineffective outreach and welfare stigma contributes to these low participation levels.
 - This contrasts with an almost 100 percent participation rate in Medicare Part B for beneficiaries.

BENEFICIARIES LACKING DRUG COVERAGE


- At least 13 million or 34 percent of Medicare beneficiaries have no insurance coverage for prescription drugs. These beneficiaries pay retail prices for prescription drugs, which can often be significantly more expensive than what large firms or public programs pay for the same drugs.

- More than half of Medicare beneficiaries without drug coverage are middle class. Over 50 percent of Medicare beneficiaries without drug coverage have incomes in excess of 150 percent – an annual income of approximately \$17,000 for couples. This indicates that targeting a drug benefit only to the low-income cannot address even half of the problem.

Many Uninsured In Middle Class

Over Half of Medicare Beneficiaries Who Lack Prescription Drug Coverage Are In The Middle Class

Income of Beneficiaries Without Drug Coverage
(As A Percent Of Poverty)




SOURCE: Actuarial Research Corporation for IRRS, 2000
In 2000, poverty for a single person is about \$8,500, for a couple is about \$11,400

- The income distribution of beneficiaries lacking drug coverage closely parallels that of all beneficiaries. This lack of difference suggests that everyone is at risk of losing their health insurance.

Lack of Insurance Affects All Medicare Beneficiaries

Income of Beneficiaries Lacking Coverage Matches That Of All Beneficiaries



SOURCE: Actuarial Research Corporation for IRRS, 2000

PRESIDENT'S PROPOSED PRESCRIPTION DRUG BENEFIT

The President's plan to modernize Medicare would include a new, voluntary Medicare drug benefit. Called Medicare Part D, it would offer all beneficiaries, for the first time, access to affordable, high-quality prescription drug coverage beginning in 2002. This benefit would cost the Federal government about \$118 billion from 2000 to 2009. It would be fully offset, primarily through savings and efficiencies in Medicare and, to a small degree, from the surplus amount dedicated to Medicare.

- **Meaningful coverage.** Beginning in 2002, beneficiaries would have the option of participating in the new Medicare Part D program. It would have:

- No deductible – coverage begins with the first prescription filled and
- 50 percent coinsurance, with access to discounts negotiated by private pharmacy managers after the limit is reached.

The benefit would be limited to \$5,000 in costs (\$2,500 in Medicare payments) in 2008. It would phase it a \$2,000 for 2002-2003; \$3,000 for 2004-2005; \$4,000 for 2006-2007; and \$5,000 in 2008 (indexed to inflation in subsequent years).

- **Affordable premiums.** Beneficiaries who opt for Part D would a pay separate premium for Medicare Part D -- an estimated \$24 per month in 2002, and \$44 per month in 2008 when fully implemented. This premium represents 50 percent of program costs. Enrollment would be optional and, after an initial open enrollment for all beneficiaries in 2001, would occur when a beneficiary becomes eligible for the program or when they transition out of employer-based coverage. Premiums would generally be deducted from Social Security checks.
 - **Low-income protections.** Beneficiaries with income up to 150 percent of poverty (\$17,000 for a couple) would pay no Part D premium. Those with income below 135 percent of poverty (\$15,000 for couples) would pay no premiums or cost sharing. This assistance would be administered through Medicaid, with the Federal government assuming all of the premium and cost sharing costs for beneficiaries with incomes above poverty.
- **Private management.** Beneficiaries in managed care plans would continue to receive their benefit through their plan. For enrollees in the traditional program, Medicare would contract with numerous private pharmacy benefit managers (PBMs) or similar entities. Medicare would use competitive bidding to award contracts for drug management. The private managers would use the latest, effective cost containment tools, drug utilization review programs, and meet quality and consumer access standards. No price controls would be imposed.
- **Incentives to develop and retain retiree coverage.** Employers that choose to offer or continue retiree drug coverage would be provided a financial incentive to do so.

APPENDIX: METHODOLOGY & ENDNOTES

Methodology. The Actuarial Research Corporation under contract with the Department of Health and Human Services conducted most of the analysis. The basis for the estimates is the Medicare Current Beneficiary Survey (MCBS) for 1995. These data were aged to CY 2000, converted to a point-in-time estimate, and adjusted for the increase in managed care enrollment. This enrollment increase was estimated by moving beneficiaries from retiree health coverage, Medigap and the uninsured to managed care in proportion to their enrollment in those plans.

Endnotes.

-
- ¹ Hazzard WR; Blass JP (Editor); Ettinger WH; Halter JB; Ouslander JG. (1998). *Principles of Geriatric Medicine and Gerontology*. New York: McGraw Hill.
 - ² Centers for Disease Control and Prevention, National Center for Health Statistics. (1993). (National High Blood Pressure Education Working Group): Report on primary prevention of hypertension. *Archives of Internal Medicine*. 153: 186.
 - ³ Wilson PWF. (1991). Established risk factors and coronary artery disease: The Framingham Study. *American Journal of Hypertension*. 7: 75.
 - ⁴ SHEP Cooperative Research Group. (1991). Prevention of stroke by hypertensive treatment in older patients with isolated systolic hypertension. *JAMA*, 265: 3255-3264.
 - ⁵ Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1388-1389.
 - ⁶ The beta-blocker heart attack trial: Beta-Blocker Heart Attack Study Group. *JAMA*. 1981; 246: 2073-2074.
 - ⁷ National Health Interview Survey.
 - ⁸ Tierney LM; McPhee SJ; Papadakis MA (editors). (1998). *Current Medical Diagnosis and Treatment 1998*. Appleton and Lange.
 - ⁹ Tierney LM, et al.; *ibid*.
 - ¹⁰ Soumerai SB; Ross-Degnan D; Avorn J; McLaughlin TJ; Choodnovskiy I. (1987). Payment restrictions for prescription drugs under Medicaid: Effects on therapy, cost and equity. *The New England Journal of Medicine*, 317: 550-556.
 - ¹¹ Families USA, 1994.
 - ¹² Soumerai SB; Ross-Degnan D; Avorn J; McLaughlin TJ; Choodnovskiy I. (1991). Effects of Medicaid drug-payment limits on admissions to hospitals and nursing homes. *The New England Journal of Medicine*, 325: 1072-1077.
 - ¹³ Bero LA.; Lipton HL; Bird, JA.. (1991). Characterization of Geriatric Drug-Related Hospital Readmissions. *Medical Care*, 29 (10): 989-1003.
 - ¹⁴ Foster Higgins, National Survey of Employer-Sponsored Health Plans, 1998.
 - ¹⁵ Foster Higgins, National Survey of Employer-Sponsored Health Plans, 1996. As reported in Hewitt Associates. (1997). Retiree Health Trends and Implications of Possible Medicare Reforms. Washington, DC: The Kaiser Medicaid Project.

OACT Estimates of Medicare Prescription Drug Options

Option 18	\$0	50%	Unlimited	50%	\$2,000	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	\$140.80
Option 19	\$100	50%	Unlimited	50%	\$1,000	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	\$98.80
Option 20	\$100	50%	Unlimited	50%	\$2,000	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	\$130.70
Option 21	\$500	50%	\$1,000	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$234.00
Option 22	\$500	50%	\$2,000	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$174.60
Option 23	\$500	25%	\$2,500	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$214.70
Option 24	\$300	10%	\$3,000	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$298.90
Option 25	\$500	25%	\$2,000	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$219.10
Option 26	\$500	25%	Unlimited	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$207.70
Option 27	\$250	25%	\$2,000	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$252.40
Option 28	\$250	25%	Unlimited	50%	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	Unlimited	\$242.80
Option 29	\$250	20%	Unlimited	50%	\$2,000	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	Indexed	\$167.40

(a) Deductibles indexed to inflation after 2001.

(b) Billions of dollars. Net budget impact reflects years 2001-2009 only.

(c) Out of Pocket limits indexed to inflation after 2001.

(d) Options 1-8 assume a 7/1/01 start date. All other options assume a 1/1/01 start date.

*Maximum benefit values are indexed to CPI.

**Estimates assume competitive bidding and award to single regional Pharmacy Benefits Manager, voluntary participation by beneficiaries, and limited enrollment periods.

Handwritten: 671p
prescription
drugs

OACT Estimates of Medicare Prescription Drug Options

[illegible]

OACT Estimates of Medicare Prescription Drug Options

[illegible]